Kanamycin km

All bacterial strains used in this study are listed in Table 1. L. monocytogenes Scott A was obtained from the International Life Sciences Institute (ILSI) North America [36 (link)] and used as the wild-type (WT) reference strain and as the parental strain for the generation of mutants. L. monocytogenes strains were grown at 30 °C in brain heart infusion (BHI; Oxoid, Hampshire, UK). E. coli DH5α [37 (link)] and S17-1λpir [38 (link)] were used as cloning hosts and as donor strains for conjugational transfer of plasmid DNA to L. monocytogenes, respectively, and were grown at 37 °C in Luria–Bertani medium (LB; 10 g/L tryptone (Thermo Fisher Scientific, Waltham, MA, USA), 5 g/L yeast extract (Thermo Fisher Scientific), 5 g/L NaCl). The growth media were supplemented with 50 µg/mL kanamycin (Km; AppliChem GmbH, Darmstadt, Germany), 100 µg/mL ampicillin (Amp; Thermo Fisher Scientific), 5–50 µg/mL polymyxin B sulfate (PMB; AppliChem GmbH), or 10 µg/mL erythromycin (Ery; Acros Organics, Geel, Belgium) as required.

The bacterial strains and plasmids used in this work are listed in Table 1. The L. monocytogenes strains were grown at 30°C in brain heart infusion (BHI, Oxoid, Hampshire, United Kingdom) medium, whereas the E. coli and B. subtilis strains were grown in Luria-Bertani (LB; 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) medium at 37°C. Agar was added at 1.5% for solid media. The media were supplemented with kanamycin (Km; AppliChem, Darmstadt, Germany), erythromycin (Em; Acros Organics, NJ, USA), ampicillin (Amp; Thermo Fisher Scientific), and anhydrotetracycline (ATc; CaymanChem, MI, USA) when appropriate. The antimicrobial essential oil compounds used in this work include t-CIN (Acros Organics), trans-2-hexenal (Sigma-Aldrich, Saint Louis, MO, USA), and 4-hydroxy-2-nonenal (Abcam, Cambridge, GB).